R -configuration of 4-aminopyridyl-based inhibitors of CYP51 confers superior efficacy against Trypanosoma cruzi

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 434-439

  Choi, Jun Yong ^a   Calvet, Claudia M ^b,c,d   Vieira, Debora F ^b,c   Gunatilleke, Shamila S ^b,c,e   Cameron, Michael D ^a   McKerrow, James H ^b,c   Podust, Larissa M ^b,c   Roush, William R ^a  

^a Department of Chemistry Scripps Florida ^*  (United States)

^b University of California at San Francisco   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e SEATTLE UNIVERSITY   (United States)

Author keywords

CYP51; inhibitors; R configuration; T. cruzi

Indexed keywords

N INDOLYL OXOPYRIDINYL 4 AMINOPROPANYL INHIBITOR; STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHAGAS DISEASE; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; TRYPANOSOMA CRUZI;

EID: 84898038912     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500010m     Document Type: Article

References (22)

1. Becher, R.; Wirsel, S. G. Fungal cytochrome P450 sterol 14alpha-demethylase (CYP51) and azole resistance in plant and human pathogens Appl. Microbiol. Biotechnol. 2012, 95, 825-840
2. Kathiravan, M. K.; Salake, A. B.; Chothe, A. S.; Dudhe, P. B.; Watode, R. P.; Mukta, M. S.; Gadhwe, S. The biology and chemistry of antifungal agents: a review Bioorg. Med. Chem. 2012, 20, 5678-5698
3. Buckner, F. S.; Urbina, J. A. Recent developments in sterol 14-demethylase inhibitors for Chagas disease Int. J. Parasitol. Drugs Drug Resist. 2012, 2, 236-242
4. Diniz Lde, F.; Caldas, I. S.; Guedes, P. M.; Crepalde, G.; de Lana, M.; Carneiro, C. M.; Talvani, A.; Urbina, J. A.; Bahia, M. T. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi Antimicrob. Agents Chemother. 2010, 54, 2979-2986
5. Molina, J.; Martins-Filho, O.; Brener, Z.; Romanha, A. J.; Loebenberg, D.; Urbina, J. A. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts Antimicrob. Agents Chemother. 2000, 44, 150-155
6. Kraus, J. M.; Tatipaka, H. B.; McGuffin, S. A.; Chennamaneni, N. K.; Karimi, M.; Arif, J.; Verlinde, C. L.; Buckner, F. S.; Gelb, M. H. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery J. Med. Chem. 2010, 53, 3887-3898
7. Andriani, G.; Amata, E.; Beatty, J.; Clements, Z.; Coffey, B. J.; Courtemanche, G.; Devine, W.; Erath, J.; Juda, C. E.; Wawrzak, Z.; Wood, J. T.; Lepesheva, G. I.; Rodriguez, A.; Pollastri, M. P. Antitrypanosomal lead discovery: Identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth J. Med. Chem. 2013, 56, 2556-2567
8. Villalta, F.; Dobish, M. C.; Nde, P. N.; Kleshchenko, Y. Y.; Hargrove, T. Y.; Johnson, C. A.; Waterman, M. R.; Johnston, J. N.; Lepesheva, G. I. VNI cures acute and chronic experimental Chagas disease J. Infect. Dis. 2013, 208, 504-511
9. Buckner, F. S.; Wilson, A. J.; White, T. C.; Van Voorhis, W. C. Induction of resistance to azole drugs in Trypanosoma cruzi Antimicrob. Agents Chemother. 1998, 42, 3245-3250
10. Choi, J. Y.; Calvet, C. M.; Gunatilleke, S. S.; Ruiz, C.; Cameron, M. D.; McKerrow, J. H.; Podust, L. M.; Roush, W. R. Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-Chagas agents J. Med. Chem. 2013, 56, 7651-7668
11. Chen, C.-K.; Doyle, P. S.; Yermalitskaya, L. V.; Mackey, Z. B.; Ang, K. K. H.; McKerrow, J. H.; Podust, L. M. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit PLoS Negl. Trop. Dis. 2009, 3, e372
12. Chen, C.-K.; Leung, S. S. F.; Guilbert, C.; Jacobson, M. P.; McKerrow, J. H.; Podust, L. M. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole PLoS Negl. Trop. Dis. 2010, 4, e651
13. Arvela, R. K.; Leadbeater, N. E. Suzuki coupling of aryl chlorides with phenylboronic acid in water, using microwave heating with simultaneous cooling Org. Lett. 2005, 7, 2101-2104
14. Barder, T. E.; Walker, S. D.; Martinelli, J. R.; Buchwald, S. L. Catalysts for Suzuki-Miyaura coupling processes: scope and studies of the effect of ligand structure J. Am. Chem. Soc. 2005, 127, 4685-4696
15. Kudo, N.; Perseghini, M.; Fu, G. C. A versatile method for Suzuki cross-coupling reactions of nitrogen heterocycles Angew. Chem., Int. Ed. 2006, 45, 1282-1284
16. Leadbeater, N. E. Fast, easy, clean chemistry by using water as a solvent and microwave heating: the Suzuki coupling as an illustration Chem. Commun. 2005, 2881-2902
17. Tasler, S.; Mies, J.; Langa, M. Applicability aspects of transition metal-catalyzed aromatic amination protocols in medicinal chemistry Adv. Synth. Catal. 2007, 349, 2286-2300
18. Wolfe, J. P.; Buchwald, S. L. Improved functional group compatibility in the palladium-catalyzed amination of aryl bromides Tetrahedron Lett. 1997, 38, 6359-6362
19. Wolfe, J. P.; Buchwald, S. L. Scope and limitations of the Pd/BINAP-catalyzed amination of aryl bromides J. Org. Chem. 2000, 65, 1144-1157
20. Coste, J.; Lenguyen, D.; Castro, B. Pybop: a new peptide coupling reagent devoid of toxic by-product Tetrahedron Lett. 1990, 31, 205-208
21. Greer, J.; Erickson, J. W.; Baldwin, J. J.; Varney, M. D. Application of the three-dimensional structures of protein target molecules in structure-based drug design J. Med. Chem. 1994, 37, 1035-1054
22. Kuntz, I. D. Structure-based strategies for drug design and discovery Science 1992, 257, 1078-1082